The Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving Oxaliplatin

Martyn, MSN Karon; Petito, MSN Emily

doi:10.6004/jadpro.2015.6.3.8

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acupuncture has been anecdotally shown to be effective for neuropathy caused by other chemotherapies, but this has not been studied extensively (33,34). Despite conflicting results from small retrospective studies, calcium and magnesium infusions have been shown, in a phase III randomized study, to have no significant effect in reducing OIN (35,36). While duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has been shown to be effective in reducing pain for patients with painful chemotherapy-induced neuropathy, its effect in non-painful neuropathy is not well characterized (37).…”

Section: Discussionmentioning

confidence: 99%

Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

et al. 2020

View full text Add to dashboard Cite

Background/Aim: Oxaliplatin-induced neurotoxicity (OIN) can be severe and dose-limiting with clinically significant symptoms that persist for years. Few published reports have described postoperative exacerbation of OIN and more longitudinal data are needed to better characterize the phenomenon. Patients and Methods: We identified 13 patients diagnosed with colon (n=7), rectal (n=4) or pancreatic (n=2) cancer who experienced postoperative OIN exacerbation at our medical center. Charts were reviewed for demographic and clinical data regarding OIN. Results: OIN exacerbation was documented 0.5-7.0 months after the first surgery following oxaliplatin exposure, with a median duration of 10.6 months (range=1.4-86.1 months). OIN exacerbation persisted in 3/13 patients at last follow-up, and improved to pre-operative levels in 6/13 patients (with complete resolution in 4/13) within a median of 3.6 months from initial exacerbation. Conclusion: Given the widespread use of oxaliplatin in neoadjuvant and first-line treatment for gastrointestinal cancers, further study is warranted to prospectively and systematically define risks for postoperative OIN exacerbation.

show abstract

Section: Discussionmentioning

confidence: 99%

Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

et al. 2020

View full text Add to dashboard Cite

show abstract

The Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving Oxaliplatin

Abstract: groundbreaking oral abstract was presented by Charles Loprinzi at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO), addressing the controversial issue of using magnesium and cal

Cited by 1 publication

References 8 publications

Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

Contact Info

Product

Resources

About